Impact of subcutaneous versus intravenous administration of pertuzumab and trastuzumab (PH) for the treatment of HER2-positive breast cancer in Montenegro. (November 2022) - Cicmil Saric, N.; Lekic, S.; Lakicevic, J.; Todorovic, V.